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ABSTRACT
Bleomycin lung toxicity is well established and can manifest as bleomycin-induced pneumonitis, but pneumomediastinum and pneumothorax 
are very rare complications. We report the case of a 73-year-old woman, recently treated with bleomycin for Hodgkin’s disease, who was 
admitted for bleomycin-induced pneumonitis. Two weeks later she had a pneumomediastinum with extensive subcutaneous emphysema 
and small bilateral pneumothoraces. Three months after that she was readmitted for dyspnoea. The CT scan showed complete regression of 
the pneumomediastinum but extensive bilateral ground-glass infiltrates. The patient died from respiratory failure 2 weeks later.
LEARNING POINTS
• Respiratory investigation before initiation of bleomycin treatment and then close follow-up during treatment of any abnormalities 
found is mandatory, as bleomycin -induced toxicity can lead to fibrosis and secondary pneumothorax /pneumomediastinum with high 
morbidity/mortality. 
• Bleomycin-induce pneumonitis (BIP) is managed with bleomycin discontinuation (Grade 1A) and system corticosteroid (Grade 1B).
• Supplemental oxygen is discouraged for BIP, but indicated for conservative management of pneumothoraces, so this case was managed 
with limited oxygen supplementation (aiming for oxygen saturation of 92–94%).
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CASE DESCRIPTION
A 73-year-old woman who had never smoked and had been recently diagnosed with Hodgkin’s lymphoma stage IIIB, was treated with two 
cycles of ABVD (adriamycin, bleomycin, vinblastine and dacarbazine) with a total dose of bleomycin of 200×103 units for 57 kg. The PET-CT 
scan after two cycles showed complete radiological and metabolic remission. However, a few days before the third cycle of chemotherapy, 
the patient developed rapidly progressive dyspnoea and a dry cough limiting her physical activity, together with mild hypoxaemia and 
bilateral lung crackles. A CT scan of the chest showed airspace consolidation, linear opacities, septal thickening especially at the bases, and 
traction bronchiectasis (Fig. 1). We diagnosed bleomycin-induced pneumonitis (BIP) because of the temporal relationship between the lung 
fibrosis and the treatment, and because of the absence of a differential diagnosis. We therefore stopped bleomycin and started systemic 
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corticosteroids (1 mg/kg of body weight). Two weeks later, the patient complained of facial and neck swelling, dyspnoea and rhinolalia.
There was no history of emesis, trauma or strenuous physical activity. Oxygen saturation was 90% by pulse oximetry (SpO2) on room 
air. A chest CT scan showed, in addition to the above findings, a pneumomediastinum, small bilateral pneumothoraces and subcutaneous 
emphysema (Fig. 2). The patient was admitted for close observation and supplemental oxygen, aiming for SpO
2
 of 92–94%. Cough and 
constipation were treated proactively to minimize subsequent Valsalva manoeuvres. A Gastrografin transit time x-ray, bronchoscopy and 
gastroscopy were performed but did not reveal the source of the mediastinal air leak. Bronchoalveolar lavage showed a mixed alveolitis with 
mild eosinophilia and ruled out pneumocystis pneumonia. The patient was discharged home after 1 month in hospital. A follow-up CT scan 
2 months after the initial admission showed subtotal resolution of the pneumomediastinum. One month later, the patient was readmitted 
for dyspnoea. The CT scan showed complete regression of the pneumomediastinum but extensive bilateral ground-glass infiltrates. The 
patient’s respiratory condition rapidly worsened and she died from respiratory failure 2 weeks later. Retrospective review of a pre-ABVD 
CT scan showed discrete pre-existing subpleural lung infiltrates, possibly caused by lymphoma or pre-existing interstitial lung disease.
Figure 1. Diagnosis of bleomycin-induced pneumonitis: airspace consolidation, linear 
opacities, septal thickening and traction bronchiectasis
Methods and procedures 
We searched PubMed using the keywords ‘bleomycin’, ‘pulmonary interstitial disease’, ‘pneumomediastinum’, ‘pneumothorax’ and ‘treatment’. 
Our search retrieved 10 articles, all of which were case reports published from 1985 to 2017, and described 10 adult male patients and 1 
male child. Four of the patients had pneumomediastinum and pneumothorax, five had pneumomediastinum only and two pneumothorax 
only. Nine were treated with steroids and five with antibiotics. Three patients completely recovered in 1–7 months, seven died after a few 
days of respiratory distress, and two died from septic shock after 7 and 30 days [1-10]. 
DISCUSSION
After the diagnosis was made, we stopped bleomycin treatment and started systemic corticosteroid therapy (1 mg/kg of body weight). The 
cytotoxic agent bleomycin can sometimes induce potentially fatal pulmonary toxicity, also known as BIP. BIP starts with an inflammatory 
reaction modifying the lung architecture and leading to pulmonary fibrosis. Besides bleomycin discontinuation, there is no effective treatment 
for BIP in humans, although systemic corticosteroids are widely prescribed[11]. We treated our patient with limited oxygen supplementation, 
aiming for SpO
2
 of 92–94%. Data obtained from animal studies suggest oxygen supplementation should not be given during bleomycin 
therapy as high oxygen concentrations encourage free radical production, which may increase bleomycin lung toxicity[12-13].
We prescribed codeine and laxatives to avoid spontaneous cough and constipation (Valsalva manoeuvres). Spontaneous pneumomediastinum 
(SPM) is defined as radiologically detected free air in the mediastinum, without preceding trauma[14]. It is mostly seen after intrathoracic 
pressure shifts leading to alveolar rupture and dissection[15]. Pneumomediastinum in patients with pulmonary fibrosis is thought to be the 
Figure 2. Pneumomediastinum with subcutaneous emphysema (green arrow)
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result of rupture of alveoli or honeycomb cysts[12,15]. Sahni et al. published a review that included 201 patients with SPM[12]. 
The most frequent triggering events were emesis, strenuous physical activity and cough. SPM is usually managed conservatively (analgesics, 
rest, oxygen therapy, bronchodilators and occasionally antibiotic treatment) and follows a benign course[12]. Our patient did not receive 
antibiotics as she never showed any symptoms or signs of infection.
A retrospective review of a pre-ABVD CT scan showed pre-existing interstitial lung disease (discrete subpleural lung infiltrates) and 
moderately reduced CO diffusion. The pre-ABVD spirometry was normal. The origin of the interstitial lung disease has not been determined, 
and may have affected lung pathology.
Retrospectively, based on the pre-treatment abnormalities, the case could have been handled differently. There is no absolute contraindication 
but perhaps the bleomycin dosage should have been discussed. 
This case report raises various points. First, before bleomycin treatment is started, respiratory investigations are mandatory. If any 
abnormality is detected, closer follow-up of the patient during treatment must be established. Second, supplemental oxygen is discouraged 
for BIP but indicated for conservative management of pneumothoraces, making oxygen management difficult in this situation. Third, despite 
numerous investigations (including CT scans, a Gastrografin transit time x-ray, gastroscopy and bronchoalveolar lavage), we never found a 
source of mediastinal air leak, which highlights the difficulty of managing these BIP-related complications.
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